Should You Invest in Processa Pharmaceuticals Inc. (PCSA) Now?

, and the 36-month beta value for PCSA is at 0.19. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

The average price suggested by analysts for PCSA is $3.00, which is $2.32 above the current market price. The public float for PCSA is 12.11M, and currently, shorts hold a 1.66% of that float. The average trading volume for PCSA on June 15, 2023 was 85.11K shares.

PCSA) stock’s latest price update

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) has seen a decline in its stock price by -1.75 in relation to its previous close of 0.69. However, the company has experienced a 4.32% gain in its stock price over the last five trading sessions.

PCSA’s Market Performance

Processa Pharmaceuticals Inc. (PCSA) has experienced a 4.32% rise in stock performance for the past week, with a 2.90% rise in the past month, and a 31.93% rise in the past quarter. The volatility ratio for the week is 19.84%, and the volatility levels for the past 30 days are at 12.68% for PCSA. The simple moving average for the past 20 days is 4.46% for PCSA’s stock, with a -48.67% simple moving average for the past 200 days.

PCSA Trading at 12.56% from the 50-Day Moving Average

After a stumble in the market that brought PCSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.27% of loss for the given period.

Volatility was left at 12.68%, however, over the last 30 days, the volatility rate increased by 19.84%, as shares surge +12.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +39.79% upper at present.

During the last 5 trading sessions, PCSA rose by +4.32%, which changed the moving average for the period of 200-days by -77.36% in comparison to the 20-day moving average, which settled at $0.6528. In addition, Processa Pharmaceuticals Inc. saw -38.35% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PCSA starting from Young David, who purchase 40,000 shares at the price of $0.80 back on Jun 12. After this action, Young David now owns 470,424 shares of Processa Pharmaceuticals Inc., valued at $32,000 using the latest closing price.

Young David, the President & CEO of Processa Pharmaceuticals Inc., purchase 20,000 shares at $0.55 during a trade that took place back on Apr 14, which means that Young David is holding 430,424 shares at $10,998 based on the most recent closing price.

Stock Fundamentals for PCSA

Equity return is now at value -205.50, with -184.10 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 8.40.


In conclusion, Processa Pharmaceuticals Inc. (PCSA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.